Clinical Trial Update: Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing two formulations of a fixed-dose combination of Tenofovir disoproxil fumarate 300 mg and Emtricitabine 200 mg; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome

Drugs mentioned

• Emtricitabine (Emtricitabine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Sponsor: Laboratorio Elea Phoenix S.A. | Conditions: Acquired Immunodeficiency Syndrome | Phase 1 | Status: COMPLETED